Abstract: The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the formulae are as set forth in the specification) or a pharmaceutically acceptable salt thereof can have a therapeutic and/or prophylactic effect on SWI/SNF complex-dysfunction cancer. A pharmaceutical composition, which is for treating and/or preventing cancer and contains a CBP/P300 inhibitor, can be provided. The cancer may be SWI/SNF complex-dysfunction cancer. The SWI/SNF complex-dysfunction cancer may be BAF complex-dysfunction cancer. The BAF complex-dysfunction cancer may be SMARC-deficient cancer, ARID-deficient cancer, or SS18-SSX fusion cancer. The SMARC-deficient cancer may be SMARCB1-deficient cancer, SMARCA2-deficient cancer, SMARCA4-deficient cancer, or SMARCA2/A4-deficient cancer.

Abstract: The present invention provides a method for treating SWI/SNF complex-deficient cancers comprising a glutathione (GSH) metabolic pathway inhibitor, a pharmaceutical composition comprising a glutathione (GSH) metabolic pathway inhibitor for therapy in SWI/SNF complex-deficient cancers, and a glutathione (GSH) metabolic pathway inhibitor for use in treating SWI/SNF complex-deficient cancers. The present invention also provides a method for detecting and/or selecting a susceptible patient to a glutathione (GSH) metabolic pathway inhibitor.

Abstract: It has been found that CBP and p300 are in the relationship of synthetic lethality, and treatment inhibiting p300 is a promising approach for the treatment of CBP-mutated cancer. It has also been revealed that this therapeutic strategy achieves efficient treatment based on companion diagnostics because a p300 inhibitor can be administered to a cancer patient selected with functional suppression of CBP as an index.

Abstract: It has been found that CBP and p300 are in the relationship of synthetic lethality, and treatment inhibiting p300 is a promising approach for the treatment of CBP-mutated cancer. It has also been revealed that this therapeutic strategy achieves efficient treatment based on companion diagnostics because a p300 inhibitor can be administered to a cancer patient selected with functional suppression of CBP as an index.

Abstract: An image processing apparatus has an image combining function in which a plurality of pages of image data is scanned, the plurality of pages of the scanned image data is combined into one page, and the combined image data is printed on a single sheet of recording paper. The image processing apparatus comprises a scanner which scans the plurality of pages of the image data. Each of the plurality of pages of the image data has a size different from each other. The image processing apparatus also has a printer which prints image data on a sheet of the recording paper. Further, the image processing apparatus comprises a controller which determines the image data having a largest size among the plurality of pages of the scanned image data. The controller determines a size of a sheet of the recording paper, based on the determined largest size.

Abstract: An image processing apparatus has an image combining function in which a plurality of pages of image data is scanned, the plurality of pages of the scanned image data is combined into one page, and the combined image data is printed on a single sheet of recording paper. The image processing apparatus comprises a scanner which scans the plurality of pages of the image data. Each of the plurality of pages of the image data has a size different from each other. The image processing apparatus also has a printer which prints image data on a sheet of the recording paper. Further, the image processing apparatus comprises a controller which determines the image data having a largest size among the plurality of pages of the scanned image data. The controller determines a size of a sheet of the recording paper, based on the determined largest size.